Heidrun Bosch‐Traberg
About
Heidrun Bosch‐Traberg is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery.
According to data from OpenAlex, Heidrun Bosch‐Traberg has authored 25 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in Heidrun Bosch‐Traberg's work include Diabetes Treatment and Management (23 papers), Metabolism, Diabetes, and Cancer (16 papers) and Diabetes Management and Research (10 papers). Heidrun Bosch‐Traberg is often cited by papers focused on Diabetes Treatment and Management (23 papers), Metabolism, Diabetes, and Cancer (16 papers) and Diabetes Management and Research (10 papers). Heidrun Bosch‐Traberg collaborates with scholars based in Denmark, United States and United Kingdom. Heidrun Bosch‐Traberg's co-authors include Peter Rossing, Katherine R. Tuttle, Johannes F.E. Mann, Kenneth W. Mahaffey, Thomas Idorn, George L. Bakris, Richard Pratley, Florian M.M. Baeres, Nanna L. Lausvig and Vlado Perkovic and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Diabetes Care.
In The Last Decade
Heidrun Bosch‐Traberg
25 papers receiving 1.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Heidrun Bosch‐Traberg Denmark | 14 | 1.2k | 462 | 425 | 286 | 196 | 25 | 1.5k | ||
| Albert Fung United States | 13 | 1.2k 1.0× | 534 1.2× | 587 1.4× | 255 0.9× | 126 0.6× | 16 | 1.4k | ||
| Thomas Idorn Denmark | 19 | 1.6k 1.3× | 498 1.1× | 645 1.5× | 367 1.3× | 317 1.6× | 44 | 2.1k | ||
| Nanna L. Lausvig United States | 7 | 816 0.7× | 335 0.7× | 207 0.5× | 213 0.7× | 116 0.6× | 7 | 1.0k | ||
| Richard Pratley United States | 6 | 746 0.6× | 197 0.4× | 233 0.5× | 187 0.7× | 161 0.8× | 9 | 997 | ||
| Silvina Gallo United States | 10 | 1.3k 1.1× | 596 1.3× | 521 1.2× | 177 0.6× | 116 0.6× | 14 | 1.5k | ||
| Gabriel Kim Germany | 10 | 1.3k 1.1× | 684 1.5× | 656 1.5× | 241 0.8× | 104 0.5× | 16 | 1.4k | ||
| Bruce R. Leslie United States | 8 | 956 0.8× | 389 0.8× | 471 1.1× | 174 0.6× | 198 1.0× | 16 | 1.2k | ||
| Erik J.M. van Bommel Netherlands | 9 | 712 0.6× | 298 0.6× | 345 0.8× | 102 0.4× | 432 2.2× | 19 | 1.2k | ||
| Mark Warren United States | 14 | 1.8k 1.5× | 745 1.6× | 643 1.5× | 380 1.3× | 79 0.4× | 32 | 2.0k | ||
| Katja Rohwedder Germany | 12 | 1.2k 1.0× | 698 1.5× | 577 1.4× | 275 1.0× | 77 0.4× | 35 | 1.3k |
Countries citing papers authored by Heidrun Bosch‐Traberg
Since
Specialization
Citations
This map shows the geographic impact of Heidrun Bosch‐Traberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidrun Bosch‐Traberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidrun Bosch‐Traberg more than expected).
Fields of papers citing papers by Heidrun Bosch‐Traberg
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Heidrun Bosch‐Traberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidrun Bosch‐Traberg. The network helps show where Heidrun Bosch‐Traberg may publish in the future.
Co-authorship network of co-authors of Heidrun Bosch‐Traberg
This figure shows the co-authorship network connecting the top 25 collaborators of Heidrun Bosch‐Traberg. A scholar is included among the top collaborators of Heidrun Bosch‐Traberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidrun Bosch‐Traberg. Heidrun Bosch‐Traberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Perkovic, Vlado, Katherine R. Tuttle, Peter Rossing, et al.. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 391(2). 109–121.
2.
Mann, Johannes F.E., Peter Rossing, George L. Bakris, et al.. (2024). Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nature Medicine. 30(10). 2849–2856.
3.
Tuttle, Katherine R., et al.. (2024). Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial. Kidney International Reports. 9(7). 2006–2015.
4.
Rossing, Peter, Florian M.M. Baeres, George L. Bakris, et al.. (2023). The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrology Dialysis Transplantation. 38(9). 2041–2051.
5.
Rossing, Peter, Stephen C. Bain, Heidrun Bosch‐Traberg, et al.. (2023). Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis. Cardiovascular Diabetology. 22(1). 220–220.
6.
Tuttle, Katherine R., Heidrun Bosch‐Traberg, David Z.I. Cherney, et al.. (2023). Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney International. 103(4). 772–781.
7.
Tuttle, Katherine R., Stephen C. Bain, Heidrun Bosch‐Traberg, et al.. (2023). #4441 KIDNEY DISEASE OUTCOMES WITH SEMAGLUTIDE VERSUS PLACEBO ACROSS BASELINE KDIGO RISK CATEGORIES: A POST HOC ANALYSIS OF SUSTAIN 6. Nephrology Dialysis Transplantation. 38(Supplement_1).
8.
Perkovic, Vlado, Florian M.M. Baeres, George L. Bakris, et al.. (2022). FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease. Nephrology Dialysis Transplantation. 37(Supplement_3).
9.
Mahaffey, Kenneth W., Florian M.M. Baeres, G. Bakris, et al.. (2022). Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial. European Heart Journal. 43(Supplement_2).
10.
Funch, Donnie, Kathleen Mortimer, Najat J. Ziyadeh, et al.. (2021). Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population. Diabetes Metabolic Syndrome and Obesity. Volume 14. 2619–2629.
11.
Staby, Arne, et al.. (2020). Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs. Pharmaceutical Research. 37(7). 120–120.
12.
Tack, Cees J., Stephan Jacob, Cyrus Desouza, et al.. (2019). Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial. Diabetes Obesity and Metabolism. 21(11). 2450–2458.
13.
Nauck, Michael A., John B. Buse, Johannes F.E. Mann, et al.. (2018). Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes Obesity and Metabolism. 21(3). 525–532.
14.
Zinman, Bernard, Michael A. Nauck, Heidrun Bosch‐Traberg, et al.. (2018). Liraglutide and Glycaemic Outcomes in the LEADER Trial. Diabetes Therapy. 9(6). 2383–2392.
15.
Tack, Cees J., Stephan Jacob, Cyrus Desouza, et al.. (2018). Liraglutide Effects in Insulin-Treated Patients in LEADER. Diabetes. 67(Supplement_1).
16.
Kaneko, Shizuka, et al.. (2017). Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical trial. Journal of Diabetes Investigation. 9(4). 840–849.
17.
Zang, Li, Ying‐Ying Liu, Jin Geng, et al.. (2016). Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26‐week, open‐label, randomized, active comparator clinical trial. Diabetes Obesity and Metabolism. 18(8). 803–811.
18.
Davies, Melanie J., Stephen C. Bain, Stephen L. Atkin, et al.. (2015). Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care. 39(2). 222–230.
19.
Kaku, Kohei, Arihiro Kiyosue, Yuri Ono, et al.. (2015). Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐group trial. Journal of Diabetes Investigation. 7(1). 76–84.
20.
Seino, Yutaka, Shizuka Kaneko, Shuichi Fukuda, et al.. (2015). Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial. Journal of Diabetes Investigation. 7(4). 565–573.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Albert Fung Breakdown of academic impact, for papers by Thomas Idorn Breakdown of academic impact, for papers by Nanna L. Lausvig Breakdown of academic impact, for papers by Richard Pratley Breakdown of academic impact, for papers by Silvina Gallo Breakdown of academic impact, for papers by Gabriel Kim Breakdown of academic impact, for papers by Bruce R. Leslie Breakdown of academic impact, for papers by Erik J.M. van Bommel Breakdown of academic impact, for papers by Mark Warren Breakdown of academic impact, for papers by Katja Rohwedder